Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Marin

Showing results (441-450 of 453) with videos related to

Pageof 46
Sort By:
Gut|September 12, 2024
Identification of PRMT5 as a therapeutic target in cholangiocarcinomaJasmin Elurbide, Leticia Colyn, Maria U Latasa, et al.
Molecular Metabolism|June 21, 2021
Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axisMarina Serrano-Maciá, Jorge Simón, Maria J González-Rellan, et al.
Hepatology (Baltimore, Md.)|November 14, 2025
NEDD8-specific protease 1 deficiency as a novel driver of hepatoblastoma development through dysregulation of the CAND1-NEDD8 pathwayL Estefanía Zapata-Pavas, Marina Serrano-Macia, Miguel Ángel Merlos Rodrigo, et al.
Cell Death & Disease|May 29, 2021
Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activityPablo Fernández-Tussy, Rubén Rodríguez-Agudo, David Fernández-Ramos, et al.
Ebiomedicine|March 25, 2026
Usefulness of plasma bile acid profile as a prognostic biomarker for drug-induced liver injuryMaria J Monte, Thi Dong-Binh Tran, Jane I Grove, et al.
Nature Reviews. Gastroenterology & Hepatology|July 2, 2020
Cholangiocarcinoma 2020: the next horizon in mechanisms and managementJesus M Banales, Jose J G Marin, Angela Lamarca, et al.
Hepatology (Baltimore, Md.)|July 28, 2025
E2F2 transcription factor promotes a cholestatic MASH phenotype by regulating hepatobiliary metabolism through miR-34a-5pMaider Apodaka-Biguri, André L Simão, Francisco González-Romero, et al.
Hepatology (Baltimore, Md.)|November 22, 2020
Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental CholangiocarcinomaLeticia Colyn, Marina Bárcena-Varela, Gloria Álvarez-Sola, et al.
Nature Reviews. Gastroenterology & Hepatology|February 9, 2023
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevanceDiego F Calvisi, Luke Boulter, Javier Vaquero, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 26, 2022
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogrammingLeticia Colyn, Gloria Alvarez-Sola, M Ujue Latasa, et al.
Pageof 46

Showing results (441-450 of 453) with videos related to

Sort By:
Pageof 46
Gut|September 12, 2024
Identification of PRMT5 as a therapeutic target in cholangiocarcinomaJasmin Elurbide, Leticia Colyn, Maria U Latasa, et al.
Molecular Metabolism|June 21, 2021
Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axisMarina Serrano-Maciá, Jorge Simón, Maria J González-Rellan, et al.
Hepatology (Baltimore, Md.)|November 14, 2025
NEDD8-specific protease 1 deficiency as a novel driver of hepatoblastoma development through dysregulation of the CAND1-NEDD8 pathwayL Estefanía Zapata-Pavas, Marina Serrano-Macia, Miguel Ángel Merlos Rodrigo, et al.
Cell Death & Disease|May 29, 2021
Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activityPablo Fernández-Tussy, Rubén Rodríguez-Agudo, David Fernández-Ramos, et al.
Ebiomedicine|March 25, 2026
Usefulness of plasma bile acid profile as a prognostic biomarker for drug-induced liver injuryMaria J Monte, Thi Dong-Binh Tran, Jane I Grove, et al.
Nature Reviews. Gastroenterology & Hepatology|July 2, 2020
Cholangiocarcinoma 2020: the next horizon in mechanisms and managementJesus M Banales, Jose J G Marin, Angela Lamarca, et al.
Hepatology (Baltimore, Md.)|July 28, 2025
E2F2 transcription factor promotes a cholestatic MASH phenotype by regulating hepatobiliary metabolism through miR-34a-5pMaider Apodaka-Biguri, André L Simão, Francisco González-Romero, et al.
Hepatology (Baltimore, Md.)|November 22, 2020
Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental CholangiocarcinomaLeticia Colyn, Marina Bárcena-Varela, Gloria Álvarez-Sola, et al.
Nature Reviews. Gastroenterology & Hepatology|February 9, 2023
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevanceDiego F Calvisi, Luke Boulter, Javier Vaquero, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 26, 2022
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogrammingLeticia Colyn, Gloria Alvarez-Sola, M Ujue Latasa, et al.
Pageof 46